ReviewFrontiers in oncology2025
Application of transcriptomics techniques in skin cancer.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer is one of the most common malignant tumors worldwide, with its mortality rate showing a significant upward trend, thereby increasing the disease burden on patients and society. With the rapid development of next-generation sequencing technology, transcriptomics has revealed complex disease mechanisms by analyzing the expression patterns of differentially expressed genes, providing important tools for exploring the occurrence and development of skin cancer, studying the tumor microenvironment, investigating drug resistance mechanisms, and optimizing treatment strategies for skin cancer. This article aims to briefly summarize the development history of transcriptomics technology, review its research progress in skin cancer, and contribute to a more comprehensive understanding of the mechanisms underlying skin cancer development. It also holds promise for identifying potential therapeutic targets and providing new insights for clinical treatment of skin cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.